TETEBENE: Effects of the Experimental Therapeutic Model Isolated Peptide Toxic-prodrug in the Treatment of Subjects with Breast Cancer and with/without Diabetes
Overview
Currently breast cancer and complications for Diabetes are the two major public health problems in Latin America. It is estmated that onde of every ten women and one in every hundred men have breast cancer; a fact that becomes more complex when a patient with diabetes are in a oncological treatment;because chemotherapy drugs and radiaton used in these processes produce a more uncontrolled glucose levels in the endocrine patient. Additionally oncological treatments are too expensive, ineffective and require a lot of medical personnel are not always available to the population that needs them. This research has resulted in the discovery of a peptide capable of inhibiting tumor cell growth, retarding the growth of murine tumors and generate an anti-inflammatory and analgesic effect, this peptide is located in the venom of two different species of scorpions, the Centruroiudes suffusus and the Rhopalurus Junceus. The purpose of this project was to design a completely new treatment for people with breast cancer based on the peptide from the venom of the scorpions suffusus, junceus, and two prodrugs (Cyclophosphamide, Traztazumab); that under certain indication of the Mexican population; studies over fifteen months on the human tumor cell lines MCF-7, T47D and HeLa and analysis on animal test subjects have shown that TETEBENE as it has bee referred to the mixture;has an average inhibition of tumor cell growth four to five times larger and a mechanism of action less harmful to the existing market; mechanism characterized by descomposiocion of active ingredients in hydroxylated intermediates,DNA junctions and antineoplastic effects on cells exhibiting overexpression of HER2.
Competition history
- ISEF 2014
Resources
Related projects
ISEF · 2015
TETEBENE: Effects of the Experimental Therapeutic Model Isolated Peptide Toxic-Prodrug in the Inhibition of Poly(ADP)Ribose Polymerase for Breast Cancer Treatment by the Use of Molecular Nanotransporters
ISEF · 2014
Developing a Unique Model to Predict the Efficacy of a Revolutionary Cancer Therapy
ISEF · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2025
Pertuzumab MMAE: A Novel ADC to Treat Drug-Resistant Breast Cancer Patients
ISEF · 2020
Targeted Breast Cancer Therapy Using Nanoparticles Modified by Tumor-Homing Peptides
ISEF · 2022
Cure of Breast Cancer - Year 5: A Novel Approach to Treating Hormonal Breast Cancer Using Diabetic Medication Through Clinical Database and 3D ex vivo Model
ISEF · 2025
TETRA-C: Accelerating Cancer Therapy Through AI-Optimized Telomerase Inhibition, Enzymatic Targeting, and the Suppression of Metastasis
JSHS · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair